ArticleInfection and immunity2002
Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades.
Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Safety and efficacy of an intramuscular bivalent vaccine against influenza and Streptococcus pneumoniae infections in mice.Medical microbiology and immunology · 2025Article
- Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development.Vaccines · 2024Review
- Immunoinformatics-aided design of a new multi-epitope vaccine adjuvanted with domain 4 of pneumolysin against Streptococcus pneumoniae strains.BMC bioinformatics · 2023Article
- A new candidate epitope-based vaccine against PspA PhtD ofFrontiers in cellular and infection microbiology · 2023Article
- Novel virulence factor Cba induces antibody-dependent enhancement (ADE) ofFrontiers in cellular and infection microbiology · 2023Article
- Review
- Protective responses of an engineered PspA recombinant antigen againstBiotechnology reports (Amsterdam, Netherlands) · 2019Article
- Prevalence of Various Vaccine Candidate Proteins in Clinical Isolates ofPathogens (Basel, Switzerland) · 2019Article
- A preliminary study on the application of PspA as a carrier for group A meningococcal polysaccharide.PloS one · 2019Article
- Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.Clinical and vaccine immunology : CVI · 2017Article
- Utilization of cholera toxin B as a mucosal adjuvant elicits antibody-mediated protection againstTherapeutic advances in vaccines · 2017Article
- Maternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspring.PloS one · 2011Article
- Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens.Infection and immunity · 2011Article
- Molecular mechanisms of the secretion of cytokines and chemokines from human monocytes activated by pneumococcal surface protein A (PspA): Roles of mitogen-activated protein kinases and NF-kappaB.Microbial pathogenesis · 2010Article
- Development of antibodies to PspA families 1 and 2 in children after exposure to Streptococcus pneumoniae.Clinical and vaccine immunology : CVI · 2008Article
- Distribution of pneumococcal surface protein A families 1 and 2 among Streptococcus pneumoniae isolates from children in finland who had acute otitis media or were nasopharyngeal carriers.Clinical and vaccine immunology : CVI · 2008Article
- Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production.Clinical and vaccine immunology : CVI · 2008Article
- Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition.Infection and immunity · 2007Article
- Optimizing expression of Streptococcus pneumoniae surface protein a, PspA: serocross-reactivity within families of antisera induced against clades 1 and 3.Molecular biotechnology · 2007Article
- Identification of a surface protein of Streptococcus suis and evaluation of its immunogenic and protective capacity in pigs.Infection and immunity · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Streptococcus pneumoniae is a major cause of disease, especially in developing countries, and cost-effective alternatives to the currently licensed vaccines are needed. We constructed DNA vaccines based on pneumococcal surface protein A (PspA), an antigen shown to induce protection against pneumococcal bacteremia. PspA fragments can be divided into three families, which can be subdivided into six clades, on the basis of PspA amino acid sequence divergence (S. K. Hollingshead, R. Becker, and D. E. Briles, Infect. Immun. 68:5889-5900, 2000). Since most clinical isolates belong to family 1 or family 2, PspA fragments from members of both of these families were analyzed. Vectors encoding the complete N-terminal regions of PspAs elicited significant humoral responses, and cross-reactivity was mainly restricted to the same family. DNA vaccines encoding fusions between PspA fragments from family 1 and family 2 were also constructed and were able to broaden the cross-reactivity, with induction of antibodies that showed reactions with members of both families. At least for the pneumococcal strains tested, the cross-reactivity of antibodies was not reflected in cross-protection. Animals immunized with DNA vaccines expressing the complete N-terminal regions of PspA fragments were protected only against intraperitoneal challenge with a strain expressing PspA from the same clade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.